Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):726-30. doi: 10.1016/j.ijrobp.2013.08.012. Epub 2013 Sep 21.
To compare the outcome of patients with invasive breast cancer both with and without lobular carcinoma in situ (LCIS)-positive/close surgical margins after breast-conserving treatment.
We retrospectively studied 2358 patients with T1-T2 invasive breast cancer treated with lumpectomy and radiation therapy from January 1980 to December 2009. Median age was 57 years (range, 24-91 years). There were 82 patients (3.5%) with positive/close LCIS margins (<0.2 cm) and 2232 patients (95.7%) with negative margins. A total of 1789 patients (76%) had negative lymph nodes. Patients who received neoadjuvant chemotherapy were excluded. A total of 1783 patients (76%) received adjuvant systemic therapy. Multivariable analysis (MVA) was performed using Cox's proportional hazards model.
The 5-year cumulative incidence of locoregional recurrence (LRR) was 3.2% (95% confidence interval [CI] 2.5%-4.1%) for the 2232 patients with LCIS-negative surgical margins (median follow-up 104 months) and 2.8% (95% CI 0.7%-10.8%) for the 82 patients with LCIS-positive/close surgical margins (median follow-up 90 months). This was not statistically significant (P=.5). On MVA, LCIS-positive margins after the final surgery were not associated with increased risk of LRR (hazard ratio [HR] 3.4, 95% CI 0.5-24.5, P=.2). Statistically significant prognostic variables on Cox's MVA for risk of LRR included systemic therapy (HR 0.5, 95% CI 0.33-0.75, P=.001), number of positive lymph nodes (HR 1.11, 95% CI 1.05-1.18, P=.001), menopausal status (HR 0.96, 95% CI 0.95-0.98, P=.001), and histopathologic grade (grade 3 vs grade 1/2) (HR 2.6, 95% CI 1.4-4.7, P=.003).
Our results suggest that the presence of LCIS at the surgical margin after lumpectomy does not increase the risk of LRR or the final outcome. These findings suggest that re-excision or mastectomy in patients with LCIS-positive/close final surgical margins is unnecessary.
比较保乳治疗后浸润性乳腺癌患者伴或不伴原位癌(LCIS)阳性/切缘接近的手术结局。
我们回顾性研究了 1980 年 1 月至 2009 年 12 月期间接受保乳切除术和放射治疗的 2358 例 T1-T2 浸润性乳腺癌患者。中位年龄为 57 岁(范围 24-91 岁)。82 例(3.5%)患者的 LCIS 切缘阳性/接近(<0.2cm),2232 例(95.7%)患者切缘阴性。共有 1789 例(76%)患者淋巴结阴性。排除接受新辅助化疗的患者。共有 1783 例(76%)患者接受辅助全身治疗。采用 Cox 比例风险模型进行多变量分析(MVA)。
2232 例 LCIS 切缘阴性患者(中位随访 104 个月)的 5 年局部区域复发(LRR)累积发生率为 3.2%(95%CI 2.5%-4.1%),82 例 LCIS 切缘阳性/接近患者为 2.8%(95%CI 0.7%-10.8%),无统计学意义(P=.5)。MVA 显示,最终手术后 LCIS 阳性切缘与 LRR 风险增加无关(风险比 [HR] 3.4,95%CI 0.5-24.5,P=.2)。Cox MVA 对 LRR 风险的显著预后变量包括系统治疗(HR 0.5,95%CI 0.33-0.75,P=.001)、阳性淋巴结数量(HR 1.11,95%CI 1.05-1.18,P=.001)、绝经状态(HR 0.96,95%CI 0.95-0.98,P=.001)和组织病理学分级(3 级 vs 1/2 级)(HR 2.6,95%CI 1.4-4.7,P=.003)。
我们的结果表明,保乳切除术后 LCIS 位于切缘并不增加 LRR 或最终结局的风险。这些发现表明,LCIS 阳性/切缘接近的患者不需要再次切除或乳房切除术。